Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Fineline Cube Apr 24, 2026
Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Fineline Cube Apr 24, 2026
Company Deals Digital

SciClone Pharmaceuticals Partners with JD Healthcare to Pioneer Integrated Immune Health Management Model

Fineline Cube Apr 24, 2026
Company Deals

Mebanks Divests Guangzhou Specialty Pharmacy Subsidiary to DaShenLin for $7.75 Million to Focus on Higher-Margin Health Insurance and Management Businesses

Fineline Cube Apr 23, 2026
Company Deals

AbbVie Announces $1.4 Billion Advanced Manufacturing Campus in North Carolina to Support Immunology, Neuroscience, and Oncology Portfolio

Fineline Cube Apr 23, 2026
Policy / Regulatory

NMPA Suspends Colchicine API Imports from Indian Manufacturers Alkaloids Bioactives and Alchem International Over Change Management Violations

Fineline Cube Apr 23, 2026
Company Drug

China Medical System’s Comekibart Anti-IL-4Rα Antibody Enters NMPA Review for Seasonal Allergic Rhinitis

Fineline Cube Apr 24, 2026
Company Drug

AbbVie Receives FDA Complete Response Letter for TrenibotE with Manufacturing Clarifications Requested

Fineline Cube Apr 24, 2026
Company Legal / IP

China Invalidates Heart Failure Patent for Dapagliflozin, Maintains Protection for Kidney Disease Use

Fineline Cube May 22, 2024

The China National Intellectual Property Administration (CNIPA) has announced a pivotal decision concerning the patent...

Company Deals

Henlius Biotech and Palleon Pharmaceuticals Modify Licensing Agreement for Bifunctional Antibody

Fineline Cube May 22, 2024

Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company based in China, has announced...

Company Legal / IP

GSK Confronted with Whistleblower Allegations Over Zantac and NDMA Link

Fineline Cube May 22, 2024

GlaxoSmithKline (GSK; NYSE: GSK), the UK-based pharmaceutical giant, is facing legal action in the form...

Company Deals

Astellas Pharma Considers Joint Cell Therapy Platform with Yaskawa Electric

Fineline Cube May 22, 2024

Astellas Pharma Inc. (TYO: 4503), a leading Japanese pharmaceutical company, has announced that it is...

Company Deals

Sanofi Leads Pharma Industry with AI Collaboration with Formation Bio and OpenAI

Fineline Cube May 22, 2024

Sanofi (NASDAQ: SNY), the France-based multinational pharmaceutical company, has announced a cutting-edge collaboration with US...

Company Drug

Eli Lilly’s Tirzepatide Earns China Approval for Type 2 Diabetes Treatment

Fineline Cube May 21, 2024

Eli Lilly & Co. (NYSE: LLY), a leading US pharmaceutical company, has announced that it...

Company Deals

Blue Sail Medical Subsidiary Secures RMB 100 Million Investment to Expand Operations

Fineline Cube May 21, 2024

China’s Blue Sail Medical Co., Ltd (SHE: 002382) has announced that Blue Sail Biosensors Medical...

Company Deals

Jiayue Pharmaceutical’s JYP0015 Secures $365 Million Licensing Agreement with Erasca

Fineline Cube May 21, 2024

Guangzhou Jiayue Pharmaceutical Technology Co., Ltd, a Chinese pharmaceutical company, has entered into a licensing...

Policy / Regulatory

China’s CDE Reports Record High in Clinical Trials for Innovative Drugs in 2023

Fineline Cube May 21, 2024

The Center for Drug Evaluation (CDE) has released its annual report, highlighting the growth in...

Company Drug

Gilead’s Seladelpar Shows Interim Benefits in PBC-Related Itch Clinical Trial

Fineline Cube May 21, 2024

Gilead Sciences (NASDAQ: GILD) has announced interim results from a long-term study assessing the safety...

Company

AstraZeneca Commits $1.5 Billion to Build Singapore-Based ADC Manufacturing Facility

Fineline Cube May 21, 2024

UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) has announced plans for a $1.5 billion greenfield...

Policy / Regulatory

NHSA Unveils 2024 Medical Procurement Overhaul, Aiming for Synergy Between National and Provincial Levels

Fineline Cube May 21, 2024

The National Healthcare Security Administration (NHSA) has issued a notification detailing plans to enhance the...

Company Medical Device

BGI Genomics Delays Market Filing for BRCA1/2 Detection Kit Due to Incomplete Data

Fineline Cube May 21, 2024

BGI Genomics Co., Ltd (SHE: 300676), a leading genomics company based in China, has announced...

Company Medical Device

Hymson Laser’s Mid Infrared Femtosecond Laser Technology Makes Medical Industry Inroads

Fineline Cube May 21, 2024

Shenzhen-based Hymson Laser Technology Group Co., Ltd (SHA: 688559) has announced a significant breakthrough with...

Company Drug

BMS’s Sotyktu Sustains Clinical Response in Long-Term Psoriasis Treatment

Fineline Cube May 21, 2024

Bristol Myers Squibb (BMS; NYSE: BMY) has announced the release of long-term clinical data for...

Policy / Regulatory

China and South Korea Reinforce Ties with Renewed MOU on Pharmaceuticals and Cosmetics Regulation

Fineline Cube May 21, 2024

The National Medical Products Administration (NMPA) of China and the Ministry of Food and Drug...

Company Deals

Pharmaron and AstraZeneca Enter Sweeping Partnership to Span Drug Development Services

Fineline Cube May 21, 2024

Pharmaron Beijing Co., Ltd, a leading Contract Research Organization (CRO) based in Beijing (HKG: 3759;...

Company Drug

Jiangsu Hengrui’s SHR1905 Anti-TSLP mAb Gets Green Light for COPD Clinical Trial

Fineline Cube May 21, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a prominent Chinese pharmaceutical company, announced that it...

Company Drug

Innovent Biologics’ IBI311 New Drug Application Accepted for Review by China’s CDE

Fineline Cube May 21, 2024

Innovent Biologics Inc., (HKG: 1801), a leading biopharmaceutical company in China, has announced that the...

Company Deals Digital Hospital

Union Hospital Teams Up with Baidu Health for AI-Enhanced Outpatient Services

Fineline Cube May 20, 2024

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, has entered into a...

Posts pagination

1 … 348 349 350 … 656

Recent updates

  • Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline
  • Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider
  • Huadong Medicine Secures NMPA Approval for Ellansé M PCL Microsphere Filler for Temple Hollowing Correction
  • Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market
  • China Medical System’s Comekibart Anti-IL-4Rα Antibody Enters NMPA Review for Seasonal Allergic Rhinitis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company R&D

Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline

Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Company Medical Device

Huadong Medicine Secures NMPA Approval for Ellansé M PCL Microsphere Filler for Temple Hollowing Correction

Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.